Study Links Popular Joint Supplement to Faster Alzheimer’s Progression

An extensive review of health records covering millions of individuals has uncovered a potential association between the commonly used joint supplement glucosamine and an accelerated shift from mild cognitive impairment to dementia, sparking fresh worries about its safety.

In this observational investigation, researchers looked at both prescription and over‑the‑counter glucosamine consumption in people diagnosed with mild cognitive impairment and discovered that regular users were roughly 25 percent more prone to develop Alzheimer’s‑type dementia during the follow‑up, compared with non‑users, after controlling for age, sex, cardiovascular risk factors and other typical medications.

Supporting laboratory experiments presented together with the epidemiological data indicate that glucosamine could intensify a pathological mechanism called O‑GlcNAcylation—an irregular addition of sugar groups to neuronal proteins—that has been linked to the creation of harmful amyloid plaques and tau tangles seen in Alzheimer’s disease.

Glucosamine, sourced from shellfish shells or manufactured synthetically, ranks among the top‑selling dietary supplements for osteoarthritis and joint discomfort, generating sales of several billion dollars each year across the United States and Europe. Historically, it has been considered low‑risk, with only rare serious side effects documented in joint‑health clinical trials.

While these results do not prove causation, they urge doctors and shoppers to balance possible cognitive hazards against the joint‑health advantages. The team intends to launch prospective trials to verify the link and to assess whether dosage, formulation, or length of use modify the observed impact. For now, healthcare providers should talk about the new evidence with patients who already have memory issues and keep an eye on cognitive shifts in those taking glucosamine.